Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a ...
NervGen Pharma (TSE:NGEN) has released an update. NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 ...
In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain. Never miss a story ...
Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions ...
Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage ...
NervGen Pharma Corp., a Vancouver-based company developing nerve-regenerating technology licensed from Case Western Reserve, raised about $7.5 million (about $10 million in Canadian dollars) from an ...
Today, Nervgen Pharma Corp shares closed at $None after opening the day at $2.88. prices ranged from a low of $2.88 to a high of $2.92. The price advanced 2.10 ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback